Tenon Medical, Inc.
TNONW
NASDAQ0.01
USD
+0.00
- -
CIK
0001560293
ISIN
US88066N1138
CUSIP
88066N113
Return %
Stock
S&P500
1Y
-66.82
15.01
3Y
-66.82
82.56
5Y
-66.82
79.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Steven Foster
- Full Time Employees
- 26
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Address
- 104 Cooper Court Los Gatos CA United States of America 95032
- IPO Date
- Jul 17, 2026
- CIK
- 0001560293
- Website
- tenonmed.com
- Similar Companies
- Business
- Tenon Medical, Inc. is a medical device company that develops and commercializes minimally invasive sacro-pelvic and sacroiliac joint fusion solutions for patients with sacroiliac joint disorders, degenerative sacroiliitis, severe lower back pain, and related sacro-pelvic fixation needs. Founded in 2012 and headquartered in Los Gatos, California, the company operates in the United States and focuses on physicians, hospitals, and surgical centers treating complex pelvic and spine conditions. Its product portfolio includes the Catamaran SI Joint Fusion System, an inferior-posterior approach using a titanium implant; the Catamaran Fixation Device; and, following its August 2025 asset acquisition of SiVantage and SIMPL Medical, the SImmetry and SImmetry+ SI joint fusion technologies, expanding its multi-approach sacro-pelvic platform. Tenon also describes a broader commercial portfolio spanning SI joint fusion, spinal fusion, and deformity adjuncts, with product development centered on achieving true biological fusion and durable fixation outcomes. Recent major changes include the August 2025 acquisition of substantially all assets of SiVantage and SIMPL Medical, integration of those technologies into Tenon’s product pipeline, continued advancement of the Catamaran platform, and preparation for commercial launch of the Catamaran SE lower-profile implant and initial alpha surgeries for SImmetry Plus. The company states that the acquisition adds revenue-generating technologies, active case volume, and a differentiated multi-product sacro-pelvic offering, supporting its strategic expansion into a broader set of pelvic anatomy approaches.